These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 32945575
1. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T. J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575 [Abstract] [Full Text] [Related]
2. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. J Vet Intern Med; 2008 Nov; 22(5):1124-35. PubMed ID: 18638016 [Abstract] [Full Text] [Related]
3. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K. J Vet Intern Med; 2013 Nov; 27(6):1452-62. PubMed ID: 24128373 [Abstract] [Full Text] [Related]
4. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080 [Abstract] [Full Text] [Related]
5. Letter regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial". Oyama MA, Gelzer AR, Kraus MS. J Vet Intern Med; 2021 Mar; 35(2):694-695. PubMed ID: 33491248 [No Abstract] [Full Text] [Related]
6. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. J Vet Intern Med; 2013 Mar; 27(6):1441-51. PubMed ID: 24010489 [Abstract] [Full Text] [Related]
7. Response to letter to editor regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial". Wess G, Glaus T, VALVE Investigators. J Vet Intern Med; 2021 Mar; 35(2):696-697. PubMed ID: 33496988 [No Abstract] [Full Text] [Related]
8. Response to letter to the editor regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial". Wess G, Glaus T, VALVE Investigators. J Vet Intern Med; 2021 Mar; 35(2):700-702. PubMed ID: 33496046 [No Abstract] [Full Text] [Related]
9. Letter to the editor regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial". Atkins C, Keene B, DeFrancesco TC, Tou S, Chetboul V, Côté É, Ettinger S, Fox PR, Hamlin RL, Mochel JP, Pouchelon JL, Stepien RL. J Vet Intern Med; 2021 Mar; 35(2):698-699. PubMed ID: 33502753 [No Abstract] [Full Text] [Related]
10. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J. J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807 [Abstract] [Full Text] [Related]
11. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P. J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723 [Abstract] [Full Text] [Related]
12. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG. J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710 [Abstract] [Full Text] [Related]
13. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE. J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078 [Abstract] [Full Text] [Related]
14. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs. Pirintr P, Saengklub N, Boonpala P, Hamlin RL, Kijtawornrat A. BMC Vet Res; 2023 Oct 12; 19(1):201. PubMed ID: 37821927 [Abstract] [Full Text] [Related]
15. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P. J Vet Intern Med; 2012 Oct 12; 26(6):1337-49. PubMed ID: 23078651 [Abstract] [Full Text] [Related]
16. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study. Besche B, Blondel T, Guillot E, Garelli-Paar C, Oyama MA. J Vet Intern Med; 2020 Sep 12; 34(5):1746-1758. PubMed ID: 32767627 [Abstract] [Full Text] [Related]
17. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. O'Grady MR, Minors SL, O'Sullivan ML, Horne R. J Vet Intern Med; 2008 Sep 12; 22(4):897-904. PubMed ID: 18537880 [Abstract] [Full Text] [Related]
18. Clinical findings and survival time in dogs with advanced heart failure. Beaumier A, Rush JE, Yang VK, Freeman LM. J Vet Intern Med; 2018 May 12; 32(3):944-950. PubMed ID: 29635788 [Abstract] [Full Text] [Related]
19. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. Chetboul V, Pouchelon JL, Menard J, Blanc J, Desquilbet L, Petit A, Rougier S, Lucats L, Woehrle F, TEST study investigators. J Vet Intern Med; 2017 Nov 12; 31(6):1629-1642. PubMed ID: 28975664 [Abstract] [Full Text] [Related]
20. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease. Yata M, Kooistra HS, Beijerink NJ. J Vet Intern Med; 2019 Mar 12; 33(2):462-470. PubMed ID: 30703246 [Abstract] [Full Text] [Related] Page: [Next] [New Search]